Health Is the New AI. The Fortunes Are Already Being Built.
The Next Wave of Capital Is Already Moving. Most Investors Will Miss It Again.
FREE READ
In 2022, the smartest investors on earth were accumulating AI positions while the rest of the world was distracted by inflation, rate hikes, and recession fears.
Nvidia was trading at $130. Meta had just been written off by every analyst on Wall Street after its metaverse pivot. Microsoft was considered a boring legacy tech company. The narrative had not yet shifted. The capital had not yet moved. But the technology was already there and the demand was already building.
I believe we are at an identical moment today. The technology is ready. The demand is building. And the narrative has not yet shifted.
The theme is health. As the defining investment theme of the next decade.
The global wellness economy hit a record $6.8 trillion in 2024. It has doubled in size since 2013 and is projected to reach $9.8 trillion by 2029. That is an economy larger than the entire pharmaceutical industry multiplied by four and growing at 7.6% annually.
The US alone spends $2.1 trillion on wellness annually. The market is not just large. It is accelerating. Mental wellness grew at 12.4% annually from 2019 to 2024. Wellness real estate at 19.5%. These are software-like growth rates in what most people still think of as a slow, defensive sector.
Now layer in the healthcare side of this equation.
Cancer treatment costs in the US are projected to reach $222 billion in 2025. Treatment for a late-stage cancer patient costs an average of $10,000 per month. New cancer drugs now cost more than $200,000 per year in 44% of all drug launches.
A University of Michigan study found that early cancer detection through screening has saved the US healthcare system at least $6.5 trillion over a 25-year period.
Read that again. $6.5 trillion saved. From early detection alone. The economic case for catching disease earlier is one of the most documented value propositions in the history of medicine.
Early cancer diagnosis is associated with longer survival, improved quality of life, and significantly lower healthcare costs. Researchers found that if all cases of melanoma, breast, lung, and colorectal cancer were diagnosed at stages one or two, national cost savings would range from $1.56 to $3.47 billion annually.
The math is not subtle. The system wants early detection. The government wants early detection. Insurers want early detection. Patients desperately want early detection. Every stakeholder in the entire healthcare value chain is aligned behind the same outcome.
Now think about how the AI trade worked in 2022.
The technology was already mature. Transformer architecture had been published. GPT-3 existed. The large language model infrastructure was being built. But the market had not yet assigned a narrative to it. The capital had not yet moved. The passive flows, the retail sentiment, the momentum buyers — none of them were there yet.
Then ChatGPT launched in November 2022. The narrative crystallized overnight. Capital flooded in. Nvidia became the most valuable company in the world. Microsoft was reborn. The big fortunes were made by the people who were already positioned.
Health and wellness is at the pre-ChatGPT moment right now.
The technology already exists. Liquid biopsy can detect cancer from a blood draw. AI can analyze genomic data in minutes that took years to process manually. Continuous health monitoring through wearables is generating datasets that were impossible to collect five years ago. Molecular surveillance of disease is transitioning from experimental to commercial at a pace that most investors have not yet registered.
The narrative has not crystallized yet. The passive flows have not moved. The retail momentum has not arrived. That is the opportunity. That is where you want to be.
Here is the part that most financial analysts miss entirely because they are not trained to think about it.
AI has a utility premium. It makes things faster, cheaper, more efficient. That is valuable. It generates enormous economic returns. But nobody cries when their email gets autocompleted. Nobody shares a video of themselves sobbing with gratitude because an AI summarized a document.
Health is different. Health is the only domain where the product literally determines whether you live or die.
A woman in her third trimester received a routine prenatal blood test. The results came back with an unexpected finding. She had Stage IV colon cancer. She was pregnant. She had chemotherapy while carrying her baby. Surgery after delivery. She is alive today because a test designed for one purpose revealed something else entirely.
That is a story about what happens when technology meets the most fundamental human need. You cannot manufacture that kind of emotional resonance. It emerges organically when the technology is genuinely life-changing.
Stories like that spread. They go on morning television. They end up in magazines. They are shared by people who have never heard of the company behind the test and suddenly cannot stop talking about it. That is how narratives crystallize.
The companies building this technology are selling years of life. That is the most valuable thing a human being can purchase. No other sector competes with that on a fundamental level.
I want to be transparent about where I personally stand. I do not write about themes I do not own. That is the founding principle of FJ Research.
I own two positions in this space.
Oscar Health is my healthcare infrastructure bet. Oscar is building the platform that connects employers, employees, and the individual health insurance market through technology that the legacy incumbents cannot replicate. The ICHRA tailwind is just beginning. The Lucie Health Marketplace just launched. Oscar recently reported $4.6 billion in quarterly revenue growing at 53% year over year with a medical loss ratio of 70.5%, significantly better than UnitedHealth’s 85%. The stock trades at roughly half the revenue multiple of its insurance peers. I am not selling a single share.
Natera is my diagnostics bet. Natera is building the molecular surveillance infrastructure of modern medicine. Its Signatera test detects circulating tumor DNA in a patient’s bloodstream weeks to months before a tumor would appear on any scan. In Q1 2026 the company processed over one million tests in a single quarter for the first time in its history. Revenue grew 39% year over year to $696.6 million. The company generated positive cash flow in the quarter. Stanley Druckenmiller, who has not had a single down year in 14 years managing George Soros’s Quantum Fund, now holds Natera as 18.14% of his disclosed portfolio. His highest conviction position. By a significant margin.
Two different entry points into the same fundamental shift. One fixing how Americans access and pay for healthcare. One detecting disease before it becomes expensive to treat and devastating to live with.
I may be two or three years ahead of the market with this thesis. The narrative crystallization I am describing may not happen in 2026. It may not happen in 2027. The passive flows may not arrive until 2028 or beyond.
The investors who made generational wealth on AI were the ones who bought it when it was still considered a gaming chip company. The thesis was correct. The timing was uncertain. The patience was the “alpha”.
I am building my health and wellness positions the same way because I know that the underlying reality will eventually force the market to price it correctly. Early detection saves $6.5 trillion. A $6.8 trillion wellness economy is growing at twice the rate of global GDP. A generation of Boomers is spending more on health than any generation in history.
The market always prices truth eventually. The question is whether you are already positioned when it does.
Wealth is health. We have known this as individuals for centuries. We say it in every language and every culture on earth. Only the investment market has been slow to fully price it.
When the market finally catches up to what patients, physicians, hospital systems, and governments already know, the companies that built the infrastructure of health and wellness in advance will be repriced dramatically.
This is not financial advice. These are my personal positions and my personal thesis. Do your own research. Size positions according to your own risk tolerance.
But if you are looking for the next wave of capital flows, the next narrative shift, the next moment where the early “believers” separate themselves from everyone who waited for consensus confirmation, I believe you are looking at it.
FJ
If you got this far, you already know the thesis resonates.
The two companies I own inside this theme — what I paid, why I bought, what has to happen for me to sell — that conversation is happening inside the paid community right now.
$49 a year. That is less than a single dinner out. And unlike the dinner, this might actually change how you think about your money.